2023
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regression
2021
Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite density
2016
Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso
Ouédraogo C, Becquey E, Wilson S, Prince L, Ouédraogo A, Rouamba N, Ouédraogo J, Vosti S, Brown K, Hess S. Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso. Food And Nutrition Bulletin 2016, 37: 529-543. PMID: 27604622, DOI: 10.1177/0379572116666167.Peer-Reviewed Original ResearchConceptsOral polio vaccineOdds ratioChildren 6High-dose vitaminVitamin A supplementsCross-sectional studyLongitudinal studyMonths old childrenCaregivers of childrenChild Health DaysMonths of ageCross-sectional surveyFalse positive reportingSupplementation coverageVAS coverageFalse positive reportsA supplementsOral vaccinePolio vaccineCoverage surveyHealth daysOlder childrenVASMonthsWeeks
2015
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrials
2011
Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites
Diakite M, Achidi E, Achonduh O, Craik R, Djimde A, Evehe M, Green A, Hubbart C, Ibrahim M, Jeffreys A, Khan B, Kimani F, Kwiatkowski D, Mbacham W, Jezan S, Ouedraogo J, Rockett K, Rowlands K, Tagelsir N, Tekete M, Zongo I, Ranford-Cartwright L. Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites. Malaria Journal 2011, 10: 250. PMID: 21867552, PMCID: PMC3177816, DOI: 10.1186/1475-2875-10-250.Peer-Reviewed Original ResearchConceptsDrug-resistant parasitesHuman genomeAnti-malarial drugsSignificant associationDrug treatmentResistant parasitesAnti-inflammatory cytokine responseTh1/Th2 balanceDrug-resistant Plasmodium falciparum parasitesDrug-resistant P. falciparumMolecular testsPlasmodium falciparum infectionPlasmodium falciparum parasitesDrug resistance profilesDrug-resistant infectionsImmune response lociCandidate gene polymorphismsAbility of parasitesTh2 balanceFalciparum infectionCytokine responsesMalaria infectionOdds ratioClearance phenotypeEnhanced clearance